Bernstein Harold 4
4 · Maze Therapeutics, Inc. · Filed Dec 31, 2025
Insider Transaction Report
Form 4
Bernstein Harold
President, R&D & CMO
Transactions
- Exercise/Conversion
Common Stock
2025-12-29$10.42/sh+45,000$468,900→ 45,000 total - Sale
Common Stock
2025-12-29$40.34/sh−27,800$1,121,424→ 17,200 total - Sale
Common Stock
2025-12-29$40.93/sh−17,200$703,931→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-12-29−45,000→ 342,407 totalExercise: $10.42Exp: 2032-10-26→ Common Stock (45,000 underlying)
Footnotes (4)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
- [F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.71 to $40.705 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.
- [F3]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.73 to $41.51 per share, inclusive.
- [F4]The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.